Market Overview - The biopharmaceutical sector experienced a slight decline of 0.08% on November 11, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Stock Performance - Notable gainers included: - Jin Ke (688670) with a closing price of 24.97, up 19.99% on a trading volume of 134,300 shares and a transaction value of 310 million [1] - Kanghua Bio (300841) closed at 83.21, up 6.04% with a trading volume of 57,100 shares [1] - Watson Bio (300142) closed at 12.82, up 2.64% with a trading volume of 942,000 shares [1] - Significant losers included: - Bu Yuan Bio (688765) closed at 86.00, down 8.02% with a trading volume of 107,600 shares [2] - Ao Pu Mai (688293) closed at 59.18, down 3.65% with a trading volume of 17,900 shares [2] - Rongchang Bio (688331) closed at 86.00, down 2.55% with a trading volume of 45,900 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 671 million from institutional investors, while retail investors contributed a net inflow of 335 million [2] - The capital flow for key stocks showed: - Jin Ke had a net inflow of 48.11 million from institutional investors, but a net outflow of 24.49 million from speculative funds [3] - Zhifei Bio (300122) experienced a net inflow of 15.25 million from institutional investors, with a net outflow of 23.20 million from retail investors [3] - Kanghua Bio had a net inflow of 14.35 million from institutional investors, but a net outflow of 23.26 million from speculative funds [3]

Group 1 - The core viewpoint of the news is that Sairun Bio's stock performance and financing activities indicate a high level of market interest, despite a slight decrease in shareholder numbers and modest revenue growth [1][2]. Group 2 - As of November 6, Sairun Bio's stock price remained unchanged, with a trading volume of 12.74 million yuan. The financing buy-in amount was 707,400 yuan, while the financing repayment was 2.13 million yuan, resulting in a net financing outflow of 1.42 million yuan [1]. - The total balance of margin trading for Sairun Bio reached 160 million yuan, accounting for 6.13% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - On the short-selling side, there were no shares repaid or sold on November 6, with the short-selling balance also at zero, which is consistent with the high percentile level over the past year [1]. Group 3 - As of September 30, the number of Sairun Bio's shareholders was 6,635, a decrease of 14.10% from the previous period. The average number of circulating shares per shareholder increased by 183.92% to 16,310 shares [2]. - For the period from January to September 2025, Sairun Bio reported a revenue of 175 million yuan, reflecting a year-on-year growth of 1.07%. The net profit attributable to the parent company was 64.21 million yuan, with a year-on-year increase of 2.01% [2]. - Since its A-share listing, Sairun Bio has distributed a total of 248 million yuan in dividends, with 150 million yuan distributed over the past three years [2].

Core Viewpoint - Shanghai Sairun Biotechnology Co., Ltd. will participate in the 2025 Shanghai-listed companies' third-quarter collective performance briefing on November 13, 2025, to address investor concerns and discuss the company's Q3 operational results and financial status [2][3]. Group 1: Event Details - The investor briefing will be held online on November 13, 2025, from 15:00 to 16:30 [6][7]. - Investors can participate by logging into the Shanghai Stock Exchange Roadshow Center website [5][6]. - The company encourages investors to submit questions from November 6 to November 12, 2025, for discussion during the briefing [2][5]. Group 2: Participants - Key participants in the briefing will include Chairman Fan Zhihe, General Manager Fan Tiejiong, Deputy General Manager and Board Secretary Cheng Qiong, Chief Financial Officer Liu Jinbao, and Independent Director Liu Junling [4]. Group 3: Contact Information - Investors can contact the company’s Board Secretary Office for inquiries via phone at 021-64959122 or email at dmb@serum-china.com [8]. - After the briefing, the main content and outcomes will be available on the Shanghai Stock Exchange Roadshow Center [8].

证券代码：688163 证券简称：赛伦生物 公告编号：2025-028 上海赛伦生物技术股份有限公司 关于参加 2025 年上海辖区上市公司三季报集体业绩 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 dmb@serum-china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海赛伦生物技术股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日披露公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 13 日 （星期 四） ...

Core Viewpoint - Sairun Bio is a leading enterprise in the field of biotoxins and biosafety drugs in China, focusing on the research, development, production, and sales of related preventive and therapeutic drugs, with strong technical barriers [1] Group 1: Business Performance - For Q3 2025, Sairun Bio reported revenue of 175 million yuan, ranking 31st out of 34 in the industry, significantly lower than the top company, Changchun High-tech, which had 9.807 billion yuan, and the second, Kanghong Pharmaceutical, with 3.624 billion yuan [2] - The net profit for the same period was 64.21 million yuan, ranking 17th in the industry, far behind the leading company, Tonghua Dongbao, which reported 1.188 billion yuan, and Changchun High-tech at 1.06 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Sairun Bio's debt-to-asset ratio was 3.14%, slightly up from 2.73% year-on-year, but significantly lower than the industry average of 26.88%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 78.43%, a slight decrease from 78.83% year-on-year, yet still above the industry average of 70.17%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders for Sairun Bio decreased by 14.10% to 6,635, while the average number of circulating A-shares held per household increased by 183.92% to 16,300 [5]

Core Points - The company, Shanghai Sailun Biotechnology Co., Ltd., ensures the authenticity, accuracy, and completeness of the quarterly report, with all board members and senior management bearing legal responsibility for any misrepresentation or omissions [2][7] - The quarterly financial statements are not audited, indicating that the financial data may not have undergone a thorough external review [3][6] - The report includes a statement regarding non-recurring gains and losses, but it is noted that there are no significant changes in the financial indicators or major accounting data [4][5] Financial Data - The financial statements for the period ending September 30, 2025, are prepared in RMB and are unaudited [6][7] - The report mentions that there were no profits recorded from mergers under common control for the current or previous periods, with both showing a net profit of 0 yuan [6]

Core Insights - The company reported a revenue of 175,138,574.09 yuan for the first three quarters of 2025, representing a year-on-year growth of 1.07% [1] - The net profit attributable to shareholders of the listed company was 64,210,654.81 yuan, showing a year-on-year increase of 2.01% [1] Financial Performance - Revenue for the first three quarters of 2025: 175.14 million yuan [1] - Year-on-year revenue growth: 1.07% [1] - Net profit for the first three quarters of 2025: 64.21 million yuan [1] - Year-on-year net profit growth: 2.01% [1]

Core Insights - Sirun Biotech (688163.SH) reported a revenue of 175 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 1.07% [1] - The company's net profit attributable to shareholders reached 64.21 million yuan, marking a year-on-year increase of 2.01% [1] - The adjusted net profit was 56.44 million yuan, showing a year-on-year growth of 12.15% [1] - Basic earnings per share stood at 0.59 yuan [1]

Core Viewpoint - SAILUN Biotech (688163.SH) reported a slight increase in revenue and net profit for the first three quarters of 2025, indicating stable growth in its financial performance [1] Financial Performance - The total operating revenue for the first three quarters reached 175 million yuan, representing a year-on-year growth of 1.07% [1] - The net profit attributable to shareholders was 64.21 million yuan, showing a year-on-year increase of 2.01% [1] - The basic earnings per share stood at 0.59 yuan [1]

Financial Performance - The company's revenue for Q3 2025 was ¥74,319,211.31, a decrease of 1.22% compared to the same period last year[3] - The total profit for the period was ¥37,052,211.73, reflecting an increase of 1.30% year-over-year[3] - The net profit attributable to shareholders was ¥31,233,921.44, up by 1.94% from the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥27,908,599.12, which increased by 1.43% compared to the same period last year[3] - The basic earnings per share for the quarter was ¥0.29, with a year-to-date figure of ¥0.59, reflecting a 1.72% increase[4] - Total operating revenue for the first three quarters of 2025 reached RMB 175,138,574.09, a slight increase from RMB 173,291,573.09 in the same period of 2024, representing a growth of approximately 1.06%[17] - Net profit for the first three quarters of 2025 was RMB 64,210,654.81, compared to RMB 62,947,540.75 in 2024, indicating an increase of approximately 2.00%[19] - The company’s total profit for the first three quarters of 2025 was RMB 74,817,469.40, compared to RMB 73,631,451.78 in 2024, reflecting an increase of approximately 1.61%[19] Assets and Liabilities - Total assets at the end of the period were ¥1,161,534,035.34, representing a 3.71% increase from the end of the previous year[4] - The company's total liabilities rose to CNY 36,453,171.78 from CNY 24,533,348.17, reflecting an increase in financial obligations[14] - The total equity attributable to shareholders increased to CNY 1,125,080,863.56 from CNY 1,095,500,608.75, showing growth in shareholder value[14] - The company's accounts receivable increased to CNY 65,179,876.60 from CNY 36,678,957.69, indicating improved sales performance[12] - The fixed assets increased to CNY 114,577,515.78 from CNY 108,979,777.03, suggesting ongoing investment in infrastructure[13] - The company reported a total non-current asset of CNY 244,024,044.52, up from CNY 203,671,011.22, reflecting long-term investment growth[13] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of ¥38,166,287.22, which decreased by 6.89% year-to-date[3] - The company's cash and cash equivalents decreased to CNY 74,948,031.35 from CNY 182,107,137.22, indicating a significant reduction in liquidity[12] - Cash flow from operating activities generated a net amount of RMB 38,166,287.22 in 2025, down from RMB 40,989,386.86 in 2024, a decrease of about 6.93%[21] - Cash flow from investing activities resulted in a net outflow of RMB 110,427,075.57 in 2025, contrasting with a net inflow of RMB 53,086,071.07 in 2024[22] - Cash and cash equivalents at the end of the third quarter of 2025 totaled RMB 74,948,031.35, a decrease from RMB 210,364,165.68 at the end of the same period in 2024[23] Research and Development - Research and development expenses totaled ¥4,402,191.05, accounting for 5.92% of revenue, an increase of 0.91 percentage points[4] - The company incurred research and development expenses of RMB 12,878,600.46 in 2025, down from RMB 16,170,774.43 in 2024, a decrease of about 20.00%[18] Non-Recurring Items - Non-recurring gains and losses for the period amounted to ¥3,325,322.32, with a year-to-date total of ¥7,774,982.99[7] - The company reported other income of RMB 497,430.05 in 2025, significantly lower than RMB 3,549,290.77 in 2024, indicating a decline of approximately 86.00%[18] Inventory and Current Assets - The total current assets slightly increased to CNY 917,509,990.82 compared to CNY 916,362,945.70 in the previous period[12] - The company's inventory decreased to CNY 38,759,460.00 from CNY 43,275,462.94, which may indicate improved inventory management[12] Operating Costs - Total operating costs decreased to RMB 105,193,973.75 in 2025 from RMB 107,900,485.01 in 2024, reflecting a reduction of about 2.52%[18]